









THE *Sumaira* FOUNDATION

	 SOLIRIS[®] (eculizumab) <small>Injection for Intravenous Use 300 mg/30 mL vial</small> Soliris[®] (eculizumab)	 UPLIZNA[®] inebilizumab-cdon Uplizna[™] (inebulizumabcdn)	 ENSPRYNG[™] Enspryng[®] (satralizumab)	 ULTOMIRIS (ravulizumab-cwvz) ULTOMIRIS[®] (ravulizumab-cwvz)
PHARMACOLOGY	Complement Inhibitor	B Cell Depletion	Interleuken-6 (IL-6) Inhibitor	Complement Inhibitor
DRUG DELIVERY METHOD	Infusion (35 minutes)	Infusion (90 minutes)	Subcutaneous Injection	IV Infusion (30 minutes to less than 1 hour)
FREQUENCY	Every 2 weeks, after 5 initial doses once per week	Every 6 months, after 2 initial doses 2 weeks apart	Every 4 weeks, after 1 dose every 2 weeks for the first 4 weeks	Every 8 weeks, 2 weeks after initial loading dose
DOSAGE	1200 mg	300 mg	120 mg	3000 – 3600 mg
ANTIBODY CRITERIA	AQP4+ NMOSD (MOG untested)	AQP4+ NMOSD (MOG untested)	AQP4+ NMOSD (MOG untested)	AQP4+ NMOSD (MOG untested)
COMMON SIDE EFFECTS	Common side effects vary, see important safety information at https://solirisnmosd.com	Common side effects vary, see important safety information at https://www.uplizna.com	Common side effects vary, see important safety information at https://www.enspryng.com	Common side effects vary, see important safety information at https://alexion.com/documents/ultomiris_uspi.pdf
POTENTIAL SERIOUS SIDE EFFECTS	Meningococcal infections and infusion reactions	infusion reactions, infections and low blood cell counts	Infections, increased liver enzymes and low neutrophil count	Meningococcal infections and infusion reactions
MANUFACTURER	 ALEXION[®] AstraZeneca Rare Disease	 AMGEN Rare Disease	 Genentech A Member of the Roche Group	 ALEXION[®] AstraZeneca Rare Disease
ASSISTANCE PROGRAMS	Alexion OneSource[™]	Amgen By Your Side	Enspryng Co-Pay Program	Alexion OneSource[™]